News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Targacept, Inc. (TRGT), AstraZeneca PLC (AZN) End Partnership on Failed Drug


5/1/2012 8:17:14 AM

One path to a billion-dollar drug discovery for Targacept Inc. officially closed Monday with the ending of its pharmaceutical collaboration on TC-5214 with AstraZeneca PLC. Targacept, an anchor tenant in Piedmont Triad Research Park, had been expecting AstraZeneca to terminate the TC-5214 licensing agreement. Last week, Targacept confirmed it would eliminate 65 jobs, or 46 percent of its workforce, in a restructuring following the failure of TC-5214 in four Phase 3 clinical trials for major depressive disorder. Targacept said other parts of its collaborative research and license agreement with AstraZeneca, which began in December 2005, remain in effect. The agreement focuses on cognitive disorders.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES